Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso
Seydou Touré, Yaobi Zhang, Elisa Bosqué-Oliva, Césaire Ky, Amado Ouedraogo, Artemis Koukounari, Albis F Gabrielli, Bertrand Sellin, Joanne P Webster, Alan Fenwick
Volume 86, Number 10, October 2008, 780-787
Table 4. Schistosoma mansoni prevalence and intensity of infection in the longitudinal cohort children before and after treatmenta
| Variable | Baseline(95% CI) | 1 year post-treatment(95% CI) | 2 years post-treatment(95% CI) |
|---|---|---|---|
| Overall (n=322) | 2.8 (1.0–4.6) | 1.6 (0.2–2.9) | 0.3 (0.0–0.9) |
| Sud Ouest (n=66) | 13.6 (5.4–21.9) | 7.6 (1.2–14.0) | 1.5 (0.0–4.5) |
| Overall (n=322) | 4.6 (0.0–9.7) | 7.0 (0.0–15.1) | 0.6 (0.0–1.8) |
| Sud Ouest (n=66) | 22.4 (0.0–47.3) | 33.8 (0.0–73.7) | 2.9 (0.0–8.7) |
CI, confidence interval; epg, number of eggs per gram of faeces.a All data at 2 years post-treatment were significantly lower than at baseline (all P < 0.05). No significant difference was found between 1 year post-treatment and baseline or between 2 years and 1 year post-treatment (P > 0.05).